Zhende Medical(SH:603301)2022-10-27 16:00Financial Performance - The company's operating revenue for Q3 2022 reached ¥1,430,511,294.36, representing a year-on-year increase of 50.49%[7] - Net profit attributable to shareholders was ¥183,469,306.96, up 75.86% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥170,655,082.65, reflecting a significant increase of 109.26% year-on-year[7] - Basic earnings per share for the quarter were ¥0.81, an increase of 76.09% from the previous year[10] - Total operating revenue for the first three quarters of 2022 reached CNY 4,197,542,725.56, an increase from CNY 3,862,648,045.72 in the same period of 2021, representing a growth of approximately 8.7%[31] - The net profit for the current period is CNY 462,971,053.32, a decrease of 21% compared to CNY 585,594,652.61 in the previous period[36] - The total profit for the current period is CNY 511,616,644.69, down from CNY 668,071,178.86, reflecting a decline of approximately 23%[36] - The operating profit stands at CNY 517,283,539.26, compared to CNY 668,686,550.96 in the previous period, indicating a decrease of about 23%[36] - The total comprehensive income attributable to the parent company's shareholders is CNY 455,043,460.39, down from CNY 482,529,812.69, reflecting a decrease of about 5.7%[38] - The basic earnings per share for the current period is CNY 2.02, a slight decrease from CNY 2.12 in the previous period[38] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥7,436,622,969.47, marking a 15.81% increase from the end of the previous year[10] - The company's total assets increased to CNY 7,436,622,969.47 from CNY 6,421,676,690.51, marking a growth of about 15.8%[33] - Total liabilities decreased to CNY 1,877,872,137.63 from CNY 1,982,076,740.76, showing a reduction of approximately 5.3%[33] - Accounts receivable reached RMB 827,060,024.40, up from RMB 690,396,879.50 in the previous year[25] Cash Flow - The company reported a net cash flow from operating activities of ¥301,735,384.37 for the year-to-date, which is a decrease of 41.35% year-on-year[10] - The cash flow from operating activities is CNY 301,735,384.37, down from CNY 514,487,076.18, representing a decline of approximately 41%[41] - The cash inflow from operating activities totaled CNY 4,888,908,254.18, an increase from CNY 4,534,671,652.40 in the previous period[41] - The cash flow from investing activities shows a net outflow of CNY 623,768,264.99, compared to a smaller outflow of CNY 37,444,008.64 in the previous period[42] - The cash flow from financing activities resulted in a net inflow of CNY 623,897,439.24, contrasting with a net outflow of CNY 282,031,429.03 in the previous period[42] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,675, with the largest shareholder, Zhejiang Zhend Medical Holdings Co., Ltd., holding 49.82% of shares[18] - The company completed a private placement of 39,246,466 shares, increasing its registered capital to RMB 266,451,202[24] - The top ten shareholders hold a combined 62.52% of the company's shares, indicating a concentrated ownership structure[18] - The company has no pledged, marked, or frozen shares among its major shareholders[18] - The largest shareholder, Zhejiang Zhend Medical Holdings Co., Ltd., also holds shares in Xuchang Zhend Landscape Engineering Co., Ltd., indicating a potential related party relationship[21] Market Strategy and Future Plans - The company plans to continue expanding its market presence and enhancing brand influence to sustain revenue growth[11] - The company plans to repurchase shares with a total amount between RMB 75 million and RMB 150 million, with a maximum price of RMB 60 per share[24] - The company has repurchased a total of 290,549 shares, representing 0.1090% of the total share capital, with a transaction amount of RMB 13,394,681.62[24] - The company has indicated a focus on strategic acquisitions to enhance its competitive position in the market[31] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[31] Research and Development - Research and development expenses amounted to CNY 160,613,197.60, compared to CNY 105,536,290.91 in the previous year, reflecting a rise of approximately 52.2%[31] Non-Recurring Gains and Losses - Non-recurring gains and losses for the quarter included government subsidies of ¥69,399,111.50, contributing to the overall profit increase[11] - The company experienced a decrease in other comprehensive income, with a net amount of CNY -41,713,592.91 compared to CNY 1,089,635.19 in the previous period[36] Revenue from Specific Products - The revenue from epidemic prevention protective products increased by 98% year-on-year, although it decreased by 27% compared to Q2 2022[11]